Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Miller, D. H.
Right arrow Articles by Kappos, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, D. H.
Right arrow Articles by Kappos, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 124, No. 5, 1052-1053, May 2001
© 2001 Oxford University Press

Letter to the Editor

MRI and assessment of treatment in multiple sclerosis

D. H. Miller1, A. J. Thompson1 and L. Kappos2

1 Institute of Neurology, London, UK and 2 Department of Neurology, University Hospitals, Basel, Switzerland

Correspondence to: Professor D. H. Miller, Institute of Neurology, Queen Square, London WC1N 3BG, UK E-mail: D.miller@ionucl.ac.uk

In an editorial commenting on a recent article on MRI evaluation of the effect of interferon beta-1b on the course of cerebral atrophy in secondary progressive multiple sclerosis (Molyneux et al., 2000Go), Professor Ebers has made a number of observations (Ebers, 2000Go). These relate both to the particular study and more generally to the role of MRI in monitoring treatment effects.

He reiterates well-known limitations in the relationship between MRI measures and disability and suggests a cautious approach in . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
M. W. Koch, J. P. Mostert, J. J. de Vries, J. De Keyser, L . Kappos, C .H. Polman, M .S. Freedman, G . Edan, H .-P. Hartung, D .H. Miller, et al.
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
Neurology, April 3, 2007; 68(14): 1163 - 1164.
[Full Text] [PDF]